Similar articles for PMID: 19585490

Year	Number of Results
1976	1
1991	1
1996	1
1997	5
1998	4
1999	1
2000	5
2001	4
2002	3
2003	9
2004	21
2005	15
2006	44
2007	58
2008	91
2009	146
2010	16
2011	15
2012	14
2013	11
2014	9
2015	5
2016	6
2017	4
2018	4
2019	3
2020	1
2021	1
2022	2
2023	0

1

Cell cycle regulator cdk2ap1 inhibits prostate cancer cell growth and modifies androgen-responsive pathway function.

Zolochevska O, Figueiredo ML. Zolochevska O, et al. Prostate. 2009 Oct 1;69(14):1586-97. doi: 10.1002/pros.21007. Prostate. 2009. PMID: 19585490

2

PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.

Litvinov IV, Antony L, Dalrymple SL, Becker R, Cheng L, Isaacs JT. Litvinov IV, et al. Prostate. 2006 Sep 1;66(12):1329-38. doi: 10.1002/pros.20483. Prostate. 2006. PMID: 16835890

3

TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.

Zhu ML, Partin JV, Bruckheimer EM, Strup SE, Kyprianou N. Zhu ML, et al. Prostate. 2008 Feb 15;68(3):287-95. doi: 10.1002/pros.20698. Prostate. 2008. PMID: 18163430

4

Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.

Sun A, Tang J, Hong Y, Song J, Terranova PF, Thrasher JB, Svojanovsky S, Wang HG, Li B. Sun A, et al. Prostate. 2008 Mar 1;68(4):453-61. doi: 10.1002/pros.20723. Prostate. 2008. PMID: 18196538

5

GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.

Tepper CG, Vinall RL, Wee CB, Xue L, Shi XB, Burich R, Mack PC, de Vere White RW. Tepper CG, et al. Prostate. 2007 Apr 1;67(5):521-35. doi: 10.1002/pros.20548. Prostate. 2007. PMID: 17252539

6

The androgen receptor and prostate cancer invasion.

Bonaccorsi L, Muratori M, Marchiani S, Forti G, Baldi E. Bonaccorsi L, et al. Mol Cell Endocrinol. 2006 Feb 26;246(1-2):157-62. doi: 10.1016/j.mce.2005.11.006. Epub 2005 Dec 20. Mol Cell Endocrinol. 2006. PMID: 16376012

7

HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.

Axlund SD, Lambert JR, Nordeen SK. Axlund SD, et al. Mol Cancer Res. 2010 Dec;8(12):1643-55. doi: 10.1158/1541-7786.MCR-10-0111. Epub 2010 Nov 2. Mol Cancer Res. 2010. PMID: 21047772

8

ACTR/AIB1/SRC-3 and androgen receptor control prostate cancer cell proliferation and tumor growth through direct control of cell cycle genes.

Zou JX, Zhong Z, Shi XB, Tepper CG, deVere White RW, Kung HJ, Chen H. Zou JX, et al. Prostate. 2006 Oct 1;66(14):1474-86. doi: 10.1002/pros.20477. Prostate. 2006. PMID: 16921507

9

Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia.

Banham AH, Boddy J, Launchbury R, Han C, Turley H, Malone PR, Harris AL, Fox SB. Banham AH, et al. Prostate. 2007 Jul 1;67(10):1091-8. doi: 10.1002/pros.20583. Prostate. 2007. PMID: 17477366

10

Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells.

Hsieh CL, Cai C, Giwa A, Bivins A, Chen SY, Sabry D, Govardhan K, Shemshedini L. Hsieh CL, et al. J Mol Endocrinol. 2008 Jul;41(1):13-23. doi: 10.1677/JME-07-0158. Epub 2008 May 9. J Mol Endocrinol. 2008. PMID: 18469090

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

453 results

Results by year